Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) developed in the 1990s as part of the broader GHRP series that emerged from medicinal chemistry programs investigating ghrelin/GHS-R agonism prior to the discovery of endogenous ghrelin. Hexarelin research has produced an unusually broad mechanistic literature that extends beyond its classical pituitary GH-releasing activity to include direct cardiac effects mediated through a non-GHS-R receptor — the scavenger receptor CD36.
The compound shares structural and pharmacological features with other members of the GHRP family, including GHRP-6 and ipamorelin, but is distinguished by its potency at the growth hormone secretagogue receptor type 1a (GHS-R1a) and its well-characterized binding to cardiac CD36. The combination of these two binding sites has made hexarelin a useful research tool for dissecting GHS-R-dependent versus GHS-R-independent effects of growth hormone secretagogues in cardiovascular preclinical models.
This article reviews the published preclinical record on Hexarelin research, the dual GHS-R/CD36 mechanism, and the laboratory considerations relevant to investigators. The body of literature is unusually broad for a synthetic GHRP and continues to develop, particularly in the cardiovascular space where the CD36 mechanism remains an active subject of investigation.
Molecular Profile
Hexarelin carries the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. The molecule incorporates several non-canonical features: D-amino acids (D-2-methyl-Trp at position 2 and D-Phe at position 5), a methylated tryptophan, and a C-terminal amide. Its molecular formula is C₄₇H₅₈N₁₂O₆ and molecular weight is approximately 887.04 Da.
The non-natural modifications confer two structural properties critical to hexarelin’s pharmacology. First, the D-amino acids and methylated residues confer protease resistance, increasing the compound’s metabolic stability relative to natural L-amino-acid sequences. Second, the constrained conformation supports high-affinity binding at GHS-R1a. The peptide is water-soluble and is supplied as a lyophilized white powder produced by solid-phase peptide synthesis.
The medicinal-chemistry lineage of hexarelin is worth noting: the compound was developed from the foundational GHRP-6 scaffold through systematic substitution and modification studies aimed at improving potency and metabolic stability. The 2-methyl group on the D-tryptophan residue at position 2 was a key contributor to the improved potency relative to GHRP-6, and the D-amino-acid substitutions reflect a broader medicinal-chemistry strategy for protease-resistant peptide design. These choices place hexarelin within a clear historical context of synthetic GHRP development and clarify its relationship to related research peptides in the same class.
Mechanism of Action
Hexarelin acts through at least two distinct receptor systems. The classical mechanism involves agonism at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that binds endogenous ghrelin. GHS-R1a is highly expressed on anterior pituitary somatotrophs, where its activation triggers GH release through a Gq-PLC-IP3-Ca²⁺ signaling cascade. GHS-R1a is also expressed in hypothalamic feeding circuits and a subset of peripheral tissues.
The second mechanism involves binding to CD36, a scavenger receptor expressed in cardiomyocytes, vascular endothelium, and several other peripheral tissues. Bodart V., Bouchard J.F., McNicoll N., et al. published in Circulation Research (2002) reporting that CD36 mediates the cardiovascular actions of growth hormone-releasing peptides in the heart, with hexarelin binding directly to cardiac CD36 and producing coronary perfusion pressure responses independently of GHS-R signaling. Demers A., McNicoll N., Febbraio M., et al. subsequently characterized the molecular interaction in detail using photoaffinity crosslinking, identifying a specific CD36 fragment as the hexarelin binding site (Biochemical Journal, 2004).
This dual receptor pharmacology distinguishes hexarelin from more selective GHS-R1a agonists. Notably, Ipamorelin — a related synthetic peptide GH secretagogue — is reported to be substantially more selective for GHS-R1a and does not display the prominent cortisol or prolactin effects that have been observed in some hexarelin investigations, making it useful as a comparator in receptor-selectivity studies.
Downstream of CD36 binding in cardiac tissue, hexarelin has been reported to engage signaling pathways including AMPK activation, modulation of fatty acid metabolism (CD36 being a key scavenger receptor for long-chain fatty acid uptake), and interleukin-1 family cytokine signaling. The receptor-independent effects on cellular metabolism may reflect the unique position of CD36 at the interface of inflammation, lipid handling, and contractile function in cardiomyocytes. The combined GHS-R1a and CD36 pharmacology makes hexarelin an unusual research peptide with simultaneous activity at endocrine and metabolic-inflammatory receptor systems — a pharmacological profile that has shaped its research applications across pituitary endocrinology, cardiovascular bioenergetics, and inflammation biology.
Key Research Areas
1. Growth Hormone Releasing Activity at GHS-R1a
The classical pharmacology of hexarelin was characterized in the 1990s as part of the broader investigation of synthetic GH secretagogues. Deghenghi R., Cananzi M.M., Torsello A., et al. published findings characterizing hexarelin’s GH-releasing potency in rats and other preclinical models. The compound has been used widely in subsequent receptor pharmacology research to probe GHS-R1a signaling, and its molecular interactions with the receptor have been examined in detail through site-directed mutagenesis and structural biology approaches.
Imbimbo B.P., Mant T., Edwards M., et al. and Bowers C.Y. and colleagues conducted early pharmacology that helped establish hexarelin as one of the most potent GHRPs in the family, with reliable GH-releasing activity across rodent, dog, and primate models. The discovery of endogenous ghrelin in 1999 retrospectively clarified that the synthetic GHRPs including hexarelin were acting on the ghrelin receptor (GHS-R1a) — a mechanistic insight that placed hexarelin within a broader physiological context of orexigenic and GH-regulatory peptide signaling. The peptide remains a useful tool for GHS-R1a pharmacology studies, often deployed alongside selective antagonists such as YIL-781 or [D-Lys3]-GHRP-6 to confirm receptor-mediated effects.
2. Cardiac CD36 and Cardioprotection Research
The cardiac literature represents one of the most distinctive features of hexarelin research. Bodart V., Bouchard J.F., McNicoll N., et al. (2002), publishing in Circulation Research, demonstrated that hexarelin produces direct cardiovascular effects through binding to CD36, with downstream activation of cardiac contractile and vascular responses. Subsequent work by Demers A. et al. in Biochemical Journal (2004) used photoaffinity labeling to identify the precise CD36 fragment responsible for hexarelin binding.
The cardioprotection literature has examined hexarelin in preclinical models of myocardial ischemia-reperfusion injury, cardiac dysfunction following hypophysectomy, and chronic heart failure following myocardial infarction. A 2014 review by Mao Y., Tokudome T., Kishimoto I. in Heart Failure Reviews consolidated the cardiovascular literature and discussed the dual GHSR1a/CD36 mechanism in the context of cardiac preclinical models.
Foundational work by Locatelli V., Rossoni G., Schweiger F., et al. (1999), publishing in Endocrinology, established that hexarelin produces growth-hormone-independent cardioprotective effects in the rat — a finding that anticipated the subsequent CD36 mechanism and demonstrated that the peptide’s cardiovascular activity could not be attributed solely to its pituitary endocrine effects. Rossoni G., Locatelli V., De Gennaro Colonna V., et al. (1999), in Journal of Cardiovascular Pharmacology, extended these findings to vascular function endpoints, reporting effects on endothelial vasodilator responses in aortic preparations from hypophysectomized rats.
3. Ischemia-Reperfusion Preclinical Models
A 2017 study by Mao Y., Tokudome T., Kishimoto I., et al. published in Frontiers in Pharmacology reported that hexarelin protected rat cardiomyocytes from in vivo ischemia/reperfusion injury through an interleukin-1 signaling pathway. The findings extended the cardiac mechanistic literature by identifying additional downstream pathways engaged by hexarelin in injury contexts.
Mao Y. and colleagues have published a series of related papers examining hexarelin in chronic post-myocardial-infarction heart failure models. Mao Y., Tokudome T., Otani K., et al. (2014), in Peptides, reported that even single oral doses of hexarelin produced measurable protection of chronic cardiac function in rat post-infarction models — work that contributed to broader interest in CD36-targeted approaches in cardiovascular research. The cumulative ischemia-reperfusion literature now provides one of the more detailed mechanistic accounts of how a single synthetic peptide can engage two receptor systems (GHS-R1a and CD36) to produce convergent protective effects in cardiac tissue.
4. Comparison with Other Growth Hormone Secretagogues
Hexarelin research is frequently presented in comparison with related GH secretagogues, particularly the more selective ipamorelin and the related compounds GHRP-2 and GHRP-6. Selectivity profiles, cortisol and prolactin response patterns, and cardiovascular effects differ across the family in ways that have made these peptides useful tools for dissecting receptor-specific contributions to GH release and peripheral signaling. Investigators interested in related GH secretagogues may also find GHRP-2, CJC-1295, and Sermorelin relevant comparators in mechanistic studies.
Comparative Research Landscape
Hexarelin sits within a substantial family of GH-secretagogue research peptides, and comparison with its relatives clarifies what the compound uniquely offers as a laboratory tool.
Within the GHRP family, GHRP-6 is the structural ancestor of hexarelin and shares the core pharmacology but with lower potency at GHS-R1a. GHRP-6 also produces appetite-stimulating effects more prominently than hexarelin, reflecting differential engagement of hypothalamic feeding circuits. GHRP-2 is a synthetic relative with high GHS-R1a potency comparable to hexarelin but with somewhat different cortisol and prolactin response patterns. Ipamorelin is the most selective GHS-R1a agonist in the family, producing GH release without the cortisol and prolactin elevations sometimes reported with hexarelin or GHRP-2 — a profile that has made ipamorelin a preferred tool for studies aiming to isolate GHS-R1a-specific effects.
Among the broader class of growth-hormone-axis research peptides, Sermorelin and CJC-1295 are GHRH analogs that act through the entirely separate growth-hormone-releasing-hormone receptor (GHRHR) rather than GHS-R1a. Pairing a GHRH analog (Sermorelin, CJC-1295) with a GHRP (hexarelin, GHRP-2, GHRP-6, ipamorelin) is a well-established research approach for studying synergistic GH release, because the two receptor systems converge on somatotroph GH secretion through complementary mechanisms. Hexarelin is sometimes preferred in such combination studies because of its high potency, though more selective alternatives may be chosen when receptor-specific interpretation is required.
The CD36 binding distinguishes hexarelin most clearly from the rest of the GHRP family. While other GHRPs may have some CD36 activity, hexarelin has the best-characterized CD36 pharmacology and is the standard research peptide for studies probing this off-target receptor system. This dual-receptor profile makes hexarelin uniquely useful for cardiovascular research applications even though it may be less ideal for studies seeking pure GHS-R1a selectivity.
Research Considerations for Laboratory Use
For investigators working with Hexarelin in laboratory settings, the peptide’s aqueous solubility and well-characterized molecular profile simplify handling. Lyophilized material should be stored at −20°C or below prior to reconstitution. Reconstituted solutions are typically prepared in sterile bacteriostatic water or 0.9% saline. The compound does not require organic carrier solvents for aqueous preparation, and reconstituted material should be used promptly or stored short-term at 2–8°C consistent with stability data for the preparation.
Research-grade hexarelin is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 887.04 Da). The presence of non-canonical residues — D-2-methyl-Trp and D-Phe — and the C-terminal amide should be verified through mass spectrometric analysis. Lot-specific certificates of analysis (CoAs) documenting purity, water content, residual solvents, and sterility are standard practice for research procurement.
Research Methodology Considerations
Rigorous hexarelin experimental design must account for several methodology issues arising from the peptide’s dual-receptor pharmacology, central and peripheral effects, and the heterogeneity of preclinical models in which it has been studied.
Assay Selection and Readouts
The most commonly reported readouts in hexarelin work include serum or plasma growth hormone measurements by immunoassay in in vivo studies, intracellular calcium imaging or cAMP/IP3 assays in cells expressing GHS-R1a, contractile function measurements in isolated cardiomyocytes or perfused hearts, coronary perfusion pressure measurements in Langendorff preparations, and infarct size assessment in ischemia-reperfusion models. For CD36-pathway dissection, fatty acid uptake assays and AMPK phosphorylation by Western blot are common molecular readouts. Investigators studying central effects can use feeding behavior assays and hypothalamic c-Fos immunoreactivity as additional readouts.
Animal Models
Rat models dominate the in vivo hexarelin literature, with both Sprague-Dawley and Wistar strains commonly used in cardiac and endocrine studies. The hypophysectomized rat model, in which the pituitary has been surgically removed to eliminate GH release, has been a particularly important tool for demonstrating GH-independent cardiovascular effects of hexarelin. Mouse models, including CD36-knockout strains, have been used in mechanistic dissection of cardiac effects. Larger-animal models (dog, pig) appear in selected cardiovascular studies. Cross-species comparisons should account for differences in CD36 expression patterns and GHS-R1a distribution.
Dose-Ranging and Pharmacokinetics
Reported in vivo doses span a range that depends on route of administration and experimental endpoint. GH-release studies typically use lower doses than cardiovascular protection studies. Subcutaneous and intravenous administration are the most common parenteral routes; oral bioavailability is limited but has been examined in selected studies. The D-amino-acid substitutions confer improved metabolic stability relative to natural L-amino-acid peptides, but the peptide nonetheless has a finite plasma half-life and is cleared via renal and hepatic mechanisms.
Common Pitfalls
Several methodological pitfalls deserve attention. First, the dual GHS-R1a/CD36 pharmacology means that observed effects may reflect contributions from either or both receptor systems; attributing effects to a specific receptor requires complementary genetic or pharmacological approaches. Second, GHS-R1a antagonists (such as [D-Lys3]-GHRP-6 or YIL-781) may not fully block CD36-mediated effects, and CD36-blocking approaches require careful validation in each experimental system. Third, batch-to-batch variability in peptide purity can produce inconsistent endocrine and cardiac responses; rigorous lot characterization is important.
Characterization Standards
Beyond ≥98% HPLC purity, rigorous hexarelin work calls for high-resolution mass spectrometry to confirm molecular weight and the presence of the D-2-methyl-Trp and D-Phe residues, NMR or chiral HPLC to confirm stereochemistry, and amino acid analysis to confirm composition. C-terminal amidation should be verified by mass spectrometry. Endotoxin testing is advisable for in vivo studies and for any in vitro work involving immune-relevant readouts.
Controls and Comparators
Useful control conditions include vehicle-only, a scrambled-sequence peptide, a more selective GHS-R1a agonist (ipamorelin) for receptor-selectivity comparison, and a GHRH analog (sermorelin) for axis-specific comparison. CD36-knockout mice or pharmacological CD36 inhibitors can confirm CD36-mediated effects. GHS-R1a antagonists ([D-Lys3]-GHRP-6, YIL-781) can confirm GHS-R-mediated effects. Combination studies pairing hexarelin with a GHRH analog test for synergistic GH release.
Conclusion
Hexarelin occupies a distinctive position among synthetic growth hormone secretagogues: a hexapeptide with well-characterized agonist activity at GHS-R1a and a substantial body of preclinical work establishing direct cardiac effects mediated through binding to the non-GHS-R receptor CD36. The dual receptor pharmacology has made hexarelin a particularly useful research tool for investigators interested in dissecting GHS-R-dependent from GHS-R-independent effects of growth hormone secretagogues, especially in cardiovascular contexts.
For investigators considering hexarelin as a laboratory reagent, the published mechanistic record provides a strong foundation for hypothesis-driven experimentation in both pituitary GH biology and cardiovascular preclinical research. As with any peptide at the research stage, conclusions about clinical relevance in human systems must be drawn cautiously from preclinical data, and experimental designs should incorporate appropriate controls and validated endpoints. The combination of high GHS-R1a potency, well-documented CD36 binding, and a developed comparator literature among related GHRPs makes hexarelin one of the more useful research peptides in contemporary growth-hormone-axis and cardiovascular peptide research.
Frequently Asked Questions
What is Hexarelin?
Hexarelin is a synthetic hexapeptide member of the growth hormone-releasing peptide (GHRP) family. It was developed in the 1990s and has been investigated as both a potent agonist at the growth hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor — and as a ligand for the cardiac scavenger receptor CD36. It is produced for research purposes only and is not approved for human or veterinary use.
What research has been conducted on Hexarelin?
The Hexarelin research literature spans pituitary GH-releasing pharmacology at GHS-R1a, cardiac CD36 binding and cardioprotection in preclinical models, ischemia-reperfusion injury models, heart failure models, and comparative studies with related GH secretagogues including GHRP-2, GHRP-6, and ipamorelin. Foundational mechanistic work on CD36 binding was published in Circulation Research in 2002 by Bodart and colleagues.
How is Hexarelin used in research settings?
In published preclinical studies, Hexarelin has been administered via subcutaneous and intravenous injection in rodent and large-animal models, and added directly to isolated cardiomyocyte or pituitary cell preparations for in vitro receptor pharmacology research. Investigators should consult primary literature for model-specific parameters and obtain material with verified identity and purity documentation.
What is the purity standard for research-grade Hexarelin?
Research-grade Hexarelin is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 887.04 Da). Verification of the non-canonical residues (D-2-methyl-Trp, D-Phe) and the C-terminal amide is essential. Reputable suppliers provide lot-specific certificates of analysis documenting purity, water content, residual solvents, and sterility.
What is CD36 and why is it relevant to Hexarelin research?
CD36 is a scavenger receptor expressed in cardiomyocytes, vascular endothelium, monocytes, and other peripheral tissues. It functions in fatty acid uptake, oxidized LDL clearance, and inflammatory signaling. Hexarelin binds directly to CD36 with affinity sufficient to produce cardiovascular effects independent of GHS-R1a signaling — a property that distinguishes it from other GHRPs and makes it a useful tool for studying CD36-mediated cardiac biology.
How does Hexarelin compare to Ipamorelin in research applications?
Both Hexarelin and Ipamorelin are synthetic GH secretagogues acting at GHS-R1a, but they differ substantially in receptor selectivity and peripheral effects. Hexarelin is a potent GHS-R1a agonist that also engages CD36, often with reported cortisol and prolactin effects in some studies. Ipamorelin is reported to be more selective for GHS-R1a and does not display the prominent cortisol or prolactin effects observed with hexarelin, making it useful as a comparator in receptor-selectivity studies.
What animal models have most commonly been used in Hexarelin research?
Rat models, particularly Sprague-Dawley and Wistar strains, dominate the in vivo literature. Specialized models include the hypophysectomized rat (used to demonstrate GH-independent cardiovascular effects) and various ischemia-reperfusion and post-myocardial-infarction models. Mouse models, including CD36-knockout strains, have been used in mechanistic dissection. Larger-animal cardiovascular studies in dog and pig appear in the literature.
Why does Hexarelin sometimes produce cortisol and prolactin effects in research models?
Hexarelin’s GHS-R1a agonism, combined with possible additional pharmacology at related receptor sites, can produce non-selective endocrine responses including elevated cortisol and prolactin in some experimental settings. This pharmacology distinguishes hexarelin from the more selective ipamorelin and is a consideration in studies that require isolated GH effects. The mechanism of the cortisol and prolactin responses is not fully characterized and may involve both central and peripheral receptor systems.
How is the dual GHS-R1a/CD36 mechanism dissected in research studies?
Dissecting the dual mechanism typically requires complementary genetic and pharmacological approaches. GHS-R1a antagonists ([D-Lys3]-GHRP-6, YIL-781) can block GHS-R-mediated effects without affecting CD36 binding. CD36-knockout mice or pharmacological CD36 inhibitors can confirm CD36-mediated effects. Pairing hexarelin with a more selective GHS-R1a agonist (ipamorelin) in side-by-side studies provides additional information about which effects reflect GHS-R1a engagement and which reflect CD36 binding.
What endpoints are most informative in Hexarelin cardioprotection studies?
Common endpoints include infarct size assessment (TTC staining), cardiac function by echocardiography or invasive hemodynamics, contractile function in isolated cardiomyocytes, coronary perfusion pressure in Langendorff preparations, fatty acid uptake and metabolism, and AMPK pathway analysis. At the molecular level, CD36 expression, interleukin-1 family cytokine output, and apoptosis markers (caspase activation, TUNEL staining) are commonly reported.
References
- Bodart V, Bouchard JF, McNicoll N, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844–849. PMID: 11988484.
- Demers A, McNicoll N, Febbraio M, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochemical Journal. 2004;382(Pt 2):417–424. PMID: 15176951.
- Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844–849. PMID: 10532947.
- Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024–4031. PMID: 10465272.
- Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. Journal of Geriatric Cardiology. 2014;11(3):253–258. PMID: 25278975.
- Mao Y, Tokudome T, Kishimoto I, et al. The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway. Frontiers in Pharmacology. 2017;8:50. PMID: 28321024.
- Mao Y, Tokudome T, Otani K, et al. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014;56:156–162. PMID: 24747279.
- Rossoni G, Locatelli V, De Gennaro Colonna V, et al. Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in aortic rings of the hypophysectomized rat. Journal of Cardiovascular Pharmacology. 1999;34(3):454–460. PMID: 10470004.
- Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321–1328. PMID: 8190002.
- Broglio F, Boutignon F, Benso A, et al. EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. Journal of Endocrinological Investigation. 2002;25(8):RC26–RC28. PMID: 12240914.
- Mao Y, Tokudome T, Kishimoto I, et al. Hexarelin protects rodent pancreatic beta-cells from cytokine-induced apoptosis through CD36-dependent signaling. Biochemical and Biophysical Research Communications. 2013;432(2):349–354. PMID: 23396071.
Hexarelin is supplied for in vitro and in vivo laboratory research use only. It is not approved for human or veterinary use.
